Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Quantitative high-throughput screening assays for the discovery and development of SIRPĪ±-CD47 interaction inhibitors.

Miller TW, Amason JD, Garcin ED, Lamy L, Dranchak PK, Macarthur R, Braisted J, Rubin JS, Burgess TL, Farrell CL, Roberts DD, Inglese J.

PLoS One. 2019 Jul 5;14(7):e0218897. doi: 10.1371/journal.pone.0218897. eCollection 2019.

2.

Defining the risk landscape in the context of pathogen pollution: Toxoplasma gondii in sea otters along the Pacific Rim.

Burgess TL, Tim Tinker M, Miller MA, Bodkin JL, Murray MJ, Saarinen JA, Nichol LM, Larson S, Conrad PA, Johnson CK.

R Soc Open Sci. 2018 Jul 4;5(7):171178. doi: 10.1098/rsos.171178. eCollection 2018 Jul.

3.

Early-life exposures and Johne's disease risk in zoo ruminants.

Burgess TL, Witte CL, Rideout BA.

J Vet Diagn Invest. 2018 Jan;30(1):78-85. doi: 10.1177/1040638717735350. Epub 2017 Oct 6.

4.

Brucella Infection in Asian Sea Otters (Enhydra lutris lutris) on Bering Island, Russia.

Burgess TL, Johnson CK, Burdin A, Gill VA, Doroff AM, Tuomi P, Smith WA, Goldstein T.

J Wildl Dis. 2017 Oct;53(4):864-868. doi: 10.7589/2016-09-220. Epub 2017 Jul 17.

PMID:
28715292
5.

Are disease reservoirs special? Taxonomic and life history characteristics.

Plourde BT, Burgess TL, Eskew EA, Roth TM, Stephenson N, Foley JE.

PLoS One. 2017 Jul 13;12(7):e0180716. doi: 10.1371/journal.pone.0180716. eCollection 2017.

6.

ISOLATION AND CHARACTERIZATION OF A NOVEL MARINE BRUCELLA FROM A SOUTHERN SEA OTTER (ENHYDRA LUTRIS NEREIS), CALIFORNIA, USA.

Miller MA, Burgess TL, Dodd EM, Rhyan JC, Jang SS, Byrne BA, Gulland FM, Murray MJ, Toy-Choutka S, Conrad PA, Field CL, Sidor IF, Smith WA.

J Wildl Dis. 2017 Apr;53(2):215-227. doi: 10.7589/2015-12-326. Epub 2017 Feb 2. Erratum in: J Wildl Dis. 2017 Oct;53(4):954.

PMID:
28151078
7.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.

Hughes PE, Rex K, Caenepeel S, Yang Y, Zhang Y, Broome MA, Kha HT, Burgess TL, Amore B, Kaplan-Lefko PJ, Moriguchi J, Werner J, Damore MA, Baker D, Choquette DM, Harmange JC, Radinsky R, Kendall R, Dussault I, Coxon A.

Mol Cancer Ther. 2016 Jul;15(7):1568-79. doi: 10.1158/1535-7163.MCT-15-0871. Epub 2016 Apr 19.

8.

Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.

Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A.

Nucl Med Biol. 2013 May;40(4):458-63. doi: 10.1016/j.nucmedbio.2013.01.004. Epub 2013 Feb 28.

PMID:
23454250
9.

Molecular imaging of c-Met tyrosine kinase activity.

Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, Galban CJ, Ross BD, Rehemtulla A.

Anal Biochem. 2011 May 1;412(1):1-8. doi: 10.1016/j.ab.2011.01.028. Epub 2011 Jan 27.

10.

Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.

Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2010 Aug;9(8):2399-410. doi: 10.1158/1535-7163.MCT-10-0181. Epub 2010 Jul 27.

11.

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.

J Cell Mol Med. 2011 Sep;15(9):1999-2006. doi: 10.1111/j.1582-4934.2010.01122.x. Epub 2010 Jul 12.

12.

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.

Burgess TL, Sun J, Meyer S, Tsuruda TS, Sun J, Elliott G, Chen Q, Haniu M, Barron WF, Juan T, Zhang K, Coxon A, Kendall RL.

Mol Cancer Ther. 2010 Feb;9(2):400-9. doi: 10.1158/1535-7163.MCT-09-0824. Epub 2010 Feb 2.

13.

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.

Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE.

Cancer Res. 2010 Jan 15;70(2):639-45. doi: 10.1158/0008-5472.CAN-09-1121. Epub 2010 Jan 12.

14.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

15.

A survey of the husbandry of captive tuatara (Sphenodon spp.) in relation to factors implicated in nutritional secondary hyperparathyroidism.

Burgess TL, Gartrell BD, Blanchard B.

N Z Vet J. 2009 Dec;57(6):378-82. doi: 10.1080/00480169.2009.64732.

PMID:
19966899
16.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

17.

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.

Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2009 May;8(5):1119-25. doi: 10.1158/1535-7163.MCT-08-1032. Epub 2009 May 12.

18.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.

J Med Chem. 2008 Sep 25;51(18):5766-79. doi: 10.1021/jm8006189.

PMID:
18763753
19.

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I.

Cancer Res. 2008 Aug 15;68(16):6680-7. doi: 10.1158/0008-5472.CAN-07-6782.

20.

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.

Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I.

J Biol Chem. 2008 Feb 1;283(5):2675-83. Epub 2007 Nov 30.

21.
22.

c-Met ectodomain shedding rate correlates with malignant potential.

Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4154-62.

23.

(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.

Kim TS, Hague AB, Lee TI, Lian B, Tegley CM, Wang X, Burgess TL, Qian YX, Ross S, Tagari P, Lin CH, Mayeda C, Dao J, Jordan S, Mohr C, Cheetham J, Viswanadhan V, Tasker AS.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):87-90.

PMID:
14684304
24.

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ.

Am J Pathol. 2000 Aug;157(2):435-48.

25.

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL.

J Cell Biol. 1999 May 3;145(3):527-38.

26.

Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors.

Faust J, Lacey DL, Hunt P, Burgess TL, Scully S, Van G, Eli A, Qian Y, Shalhoub V.

J Cell Biochem. 1999 Jan 1;72(1):67-80.

PMID:
10025668
27.

Altered cell surface expression and signaling of leptin receptors containing the fatty mutation.

Crouse JA, Elliott GE, Burgess TL, Chiu L, Bennett L, Moore J, Nicolson M, Pacifici RE.

J Biol Chem. 1998 Jul 17;273(29):18365-73.

28.

Amyloid precursor protein processing in sterol regulatory element-binding protein site 2 protease-deficient Chinese hamster ovary cells.

Ross SL, Martin F, Simonet L, Jacobsen F, Deshpande R, Vassar R, Bennett B, Luo Y, Wooden S, Hu S, Citron M, Burgess TL.

J Biol Chem. 1998 Jun 19;273(25):15309-12.

29.
30.

The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.

Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al.

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4051-5.

31.

The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries.

Farrell CL, Bready JV, Kaufman SA, Qian YX, Burgess TL.

Antisense Res Dev. 1995 Fall;5(3):175-83.

PMID:
8785473
32.

Using a closed ecological system to study Earth's biosphere: initial results from Biosphere 2.

Nelson M, Burgess TL, Alling A, Alvarez-Romo N, Dempster WF, Walford RL, Allen JP.

Bioscience. 1993 Apr;43(4):225-36. No abstract available.

PMID:
11537406
33.

Disruption of the Golgi apparatus with brefeldin A does not destabilize the associated detyrosinated microtubule network.

Burgess TL, Skoufias DA, Wilson L.

Cell Motil Cytoskeleton. 1991;20(4):289-300.

PMID:
1802418
34.
35.
36.

Constitutive and regulated secretion of proteins.

Burgess TL, Kelly RB.

Annu Rev Cell Biol. 1987;3:243-93. Review. No abstract available.

PMID:
3318877
39.

Dexamethasone regulation of alpha 1-acid glycoprotein and other acute phase reactants in rat liver and hepatoma cells.

Baumann H, Firestone GL, Burgess TL, Gross KW, Yamamoto KR, Held WA.

J Biol Chem. 1983 Jan 10;258(1):563-70. No abstract available.

40.

Membrane traffic in neurons and peptide-secreting cells.

Kelly RB, Buckley KM, Burgess TL, Carlson SS, Caroni P, Hooper JE, Katzen A, Moore HP, Pfeffer SR, Schroer TA.

Cold Spring Harb Symp Quant Biol. 1983;48 Pt 2:697-705. No abstract available.

PMID:
6327173
41.

Properties of simian virus 40 small t antigen overproduced in bacteria.

Thummel CS, Burgess TL, Tjian R.

J Virol. 1981 Feb;37(2):683-97.

42.

Studies on hormonal regulation of squalene synthesis in preputial gland and skin of the rat.

BURGESS TL, WILSON JD.

Proc Soc Exp Biol Med. 1963 Jul;113:747-50. No abstract available.

PMID:
14016990
43.

Effect of MER-29 on egg production in the chicken.

BURGESS TL, BURGESS CL, WILSON JD.

Proc Soc Exp Biol Med. 1962 Jan;109:218-21. No abstract available.

PMID:
13874831

Supplemental Content

Loading ...
Support Center